Quality‐of‐life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (<scp>PATCH</scp>) trial evaluating luteinising hormone‐releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

Gilbert, Duncan C.; Duong, Trinh; Kynaston, Howard; Alhasso, Abdulla; Cafferty, Fay; Rosen, Stuart D.; Kanaga-Sundaram, Subramanian; Dixit, Sanjay; Laniado, Marc; Madaan, Sanjeev; Collins, Gerald N.; Pope, Alvan; Welland, Andrew; Nankivell, Matthew; Wassersug, Richard J.; Parmar, Mahesh; Langley, Ruth E.; Abel, Paul

doi:10.1111/bju.13687

Cited by 37 publications

(28 citation statements)

References 53 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…172 QOL outcomes and the experience of vasomotor symptoms were better at 6 months in the transdermal group compared with the agonist group, but rates of significant gynecomastia were higher in the transdermal group (37% vs 5%). 173 The PATCH trial continues enrollment to assess survival (ClinicalTrials.gov identifier: NCT00303784).…”

Section: Secondary Hormone Therapy For Crpcmentioning

confidence: 99%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,014

837

View full text Add to dashboard Cite

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

show abstract

Section: Secondary Hormone Therapy For Crpcmentioning

confidence: 99%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,014

837

View full text Add to dashboard Cite

show abstract

“…In non-blinded studies, two men with aromatase deficiency had increments in libido and sexual activity during E2 treatment, either alone (51) or with testosterone (47). Non-definitive evidence from men with prostate cancer suggests that androgen deprivation therapy (ADT) using estrogens may better maintain sexual function than surgical castration (52) and GnRH analogs (53).…”

Section: Libido and Erectile Functionmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone

Russell

Grossmann

2019

European Journal of Endocrinology

View full text Add to dashboard Cite

Evidence has been accumulating that, in men, some of the biological actions traditionally attributed to testosterone acting via the androgen receptor may in fact be dependent on its aromatization to estradiol (E2). In men, E2 circulates at concentrations exceeding those of postmenopausal women, and estrogen receptors are expressed in many male reproductive and somatic tissues. Human studies contributing evidence for the role of E2 in men comprise rare case reports of men lacking aromatase or a functional estrogen receptor alpha, short-term experiments manipulating sex steroid milieu in healthy men, men with organic hypogonadism or men with prostate cancer treated with androgen deprivation therapy (ADT) and from observational studies in community-dwelling men. The collective evidence suggests that, in men, E2 is an important hormone for hypothalamic–pituitary–testicular axis regulation, reproductive function, growth hormone insulin-like growth factor-1 axis regulation, bone growth and maintenance of skeletal health, body composition and glucose metabolism and vasomotor stability. In other tissues, particularly brain, elucidation of the clinical relevance of E2 actions requires further research. From a clinical perspective, the current evidence supports the use of testosterone as the treatment of choice in male hypogonadism, rather than aromatase inhibitors (which raise testosterone and lower E2), selective androgen receptor modulators and selective estrogen receptor modulators (with insufficiently understood tissue-specific estrogenic effects). Finally, E2 treatment, either as add-back to conventional ADT or as sole mode of ADT could be a useful strategy for men with prostate cancer.

show abstract

“…Azapeptides have been modified and tested to obstruct gama-SM protein. Another gama-SM protein inhibitor, peptide-based, have also been considered with the knowledge that its chemical composition is very advantageous for various combination therapies (68, 69). Additionally, boronic acid-based inhibitors have been determined to constrain the destruction of gama-SM substrates and its effects on gama-SM protein secretion and progression of xenografts in vivo (70, 71).…”

Section: Targeting Hsp70 and Gama-sm: A Possible Therapy For Pcamentioning

confidence: 99%

Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer

et al. 2018

View full text Add to dashboard Cite

In the United States, Prostate Cancer (PCa) is the leading cause of cancer-related mortality in men. PCa resulted in abnormal growth and function of prostate gland such as secretion of high level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) which could be detected in the blood. Beside gama-SM protein, the levels of heat shock proteins (Hsp70) were also observed significantly high. Therefore, gama-SM and Hsp70 are unique proteins with high potential for PCa therapeutics and diagnostics. High level of Hsp70 suppresses apoptosis, thus allowing PCa cells to exist; however, depletion of Hsp70 induces apoptosis in PCa cells. Gama-SM is the most prominent biomarker for PCa screening; however, its accuracy is still questionable. Thus, a more suitable streamline biomarker for PCa screening is urgently needed. Hsp70 and gama-SM proteins could be used as a revolutionary biomarker for PCa, and could help to identify possible therapeutic target(s). In this review article we will discuss the relationship between the Hsp70 and gama-SM proteins with PCa, their potential as a dual biomarker, and the possibility for both proteins being used as therapeutic targets.

show abstract

Quality‐of‐life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone‐releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

Cited by 37 publications

References 53 publications

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone

Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer

Contact Info

Product

Resources

About